CD73-adenosine reduces immune responses and survival in ovarian cancer patients

CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer

(2015) Martin Turcotte et al.   CANCER RESEARCH

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

(2015) Paul A. Beavis et al.   Cancer Immunology Research

Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor

(2014) D. Mittal et al.   CANCER RESEARCH

Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer

(2014) Bertrand Allard et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

(2013) B. Allard et al.   CLINICAL CANCER RESEARCH

CD39 and CD73 in immunity and inflammation

(2013) Luca Antonioli et al.   TRENDS IN MOLECULAR MEDICINE

CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis

(2011) J. Stagg et al.   CANCER RESEARCH

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

(2010) D. Jin et al.   CANCER RESEARCH

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors

(2009) Katy Milne et al.   PLoS One